Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer

Table 2 Local immune response in the bladder wall after PstS1 immunotherapy

group	S.C. / Intravesical Treatment	CD11b	GR-1	CD4	CD8	CD11c
1	PBS/PBS	11± 8	3 ± 2	28 ± 24	8 ± 9	2,2 ± 1,7
2	L-Particle/PBS	6 ± 7	3 ± 2	17 ± 6	4 ± 3	1,6 ± 1,4
3	L-Particle-PstS1/PBS	24 ± 20	4 ± 7	69 ± 60	16 ± 15	22,2 ± 24,4
4	PBS/PstS1	86 ± 46	44 ± 30	45 ± 18	10 ± 4	1,9 ± 2,1
5	L-Particle/PstS1	114 ± 25	56 ± 20	56 ± 16	13 ± 14	3 ± 2,4
6	L-Particle-PstS1/PstS1	143 ± 84	49 ± 15	75 ± 29	36 ± 29	4,5 ± 4,2

Five mice per group were sensitized s.c. and treated intravesically on days 10, 17, 24 and 31 as indicated in the table. On day 32 bladders were dissected and used for histochemistry. CD11b: Granulocytes and Macrophages, GR-1: Granulocytes, CD4: CD4-Lymphocytes, CD8: CD8-Lymphocytes, CD 11c: Dendritic cells. The number of positive cells in the entire bladder specimens was counted using visual fields and light microscopy. The data are depicted as the mean number of positive cells per visual field ± standard deviation (n = five mice per group).

ISSN: 1471-2407